Status:
COMPLETED
A Study To Determine The Effect Of SB-480848 On Asthma
Lead Sponsor:
GlaxoSmithKline
Conditions:
Atherosclerosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare the effects of SB-480848 with placebo in subjects with asthma.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male and female subjects who have documented persistent asthma for at least 3 months
- Subjects must have been on a stable, low-dose ICS for a minimum of 4 weeks prior to the screening visit.
- Aged 18-65 years, at screening
- FEV1 greater than or equal to 70% predicted (ECCS, 1993)
- Subjects must show an increase in FEV1 greater than or equal to 12% (and an absolute change \>200mL) within 30 minutes following inhalation of 4 puffs of albuterol/salbutamol or 1 nebulized treatment of 2.5mg or have historical, documented evidence of reversibility, within 12 months prior to screening
- Subjects must be willing to replace their inhaled, short-acting β2-agonist with study provided albuterol/salbutamol
- Patient must be capable of giving informed consent and comply with the study requirements and timetable.
- Inclusion Criteria following run in period (Prior to randomisation) Subjects will be screened based on the inclusion and exclusion criteria noted above.
- During the run-in period \[Day -14 to Day 1\], subjects will be asked to maintain a diary card and document the number of puffs of rescue inhaled, short-acting β2-agonists taken, asthma-related symptoms and night time awakenings as well as morning and evening PEF measurements.
- On the morning of Day 0, subjects will be eligible for randomisation into the study if all of the following criteria are met:
- Subjects required, on average less than or 2 puffs per day of study provided albuterol/ salbutamol during the last 7-day period prior to Day 0 \[from Day -7 to Day 1\]
- Subjects had asthma symptoms on less than or 5 out of the last 7 consecutive days of the run-in period
- FEV1 greater than or equal to 70% predicted (ECCS, 1993).
- FEV1 must be within ± 15% of the FEV1 value at beginning of screening.
- Compliance with completion of the diary card.
- Exclusion criteria:
- The patient has life threatening asthma. A research patient must not have been hospitalized two or more times in the last year prior to Day 0 due to asthma and must not have been hospitalized within 6 months prior to Day 0
- Subjects with daily asthma-related symptoms.
- Subjects taking any of the medications listed in the protocol for the listed interval prior to the screening visit or during the study:
- Subjects with historical or current evidence of any other disease.
- Subjects with clinically significant abnormal findings on physical exam or other screening procedures.
- Subjects who have received an investigational product within 30 days or 5 half-lives \[whichever is longer\] prior to the first dose of study medication
- Subjects who have tested positive for hepatitis C antibody, hepatitis B surface antigen or HIV.
- Subjects with history of drug or alcohol abuse
- Positive drug (not related to known medications the subject is taking at time of screening), alcohol or cotinine/carbon monoxide (CO) test at screening or at Day 0
- Subjects with a history of regularly drinking more than 2 (females)/3 (males) units of alcohol a day.
- Pregnant or nursing female subjects.
- Female subjects of childbearing potential with an unwillingness to agree to one of the methods of contraception listed in the protocol.
- Subjects who suffer from any medical condition which in the opinion of the investigator would compromise patient safety or ability to comply with study procedures
- Subjects who are current smokers or have given up smoking within the previous six months or who have a smoking history \> 10 pack years.
- Subjects with history of an upper or lower respiratory tract infection or symptoms (including the common cold) within 2 weeks prior to first dose of study medication
- Subjects who have donated more than 500ml of blood within 56 days prior to the first dose of study medication
- Subjects who are currently receiving potent 3A4 inhibitors be excluded.
- Subjects on β-adrenergic receptor blockers within 3 months prior to screening visit
- Subjects previously hospitalized as a result of a methacholine challenge
Exclusion
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00368576
Start Date
August 1 2006
End Date
October 1 2007
Last Update
December 5 2016
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Cypress, California, United States, 90630
2
GSK Investigational Site
Normal, Illinois, United States, 61761
3
GSK Investigational Site
North Dartmouth, Massachusetts, United States, 02747
4
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303